How does semaglutide lower blood sugar?
Semaglutide is a GLP-1 receptor agonist. It helps reduce blood glucose mainly by boosting glucose-dependent insulin release after meals, lowering glucagon, and slowing stomach emptying so glucose enters the bloodstream more gradually. These actions tend to reduce both post-meal blood sugar spikes and overall blood glucose over time [1].
What happens to fasting vs after-meal blood sugar?
Because semaglutide slows gastric emptying and improves post-meal insulin response, it commonly has a stronger effect on post-meal (postprandial) glucose levels. Over time, improved insulin regulation and lower glucagon also help lower fasting glucose, which reflects better longer-term glucose control [1].
Does semaglutide raise or lower A1C?
Semaglutide is used to improve long-term glycemic control in type 2 diabetes. That typically shows up as lower A1C (a measure of average blood sugar over about 2–3 months) as glucose control improves [1].
What are the risk and warning signs of low blood sugar?
Semaglutide by itself has a relatively low risk of hypoglycemia, because its insulin-boosting effects are glucose-dependent. The risk rises when semaglutide is used with other glucose-lowering medicines that can cause hypoglycemia, especially insulin or sulfonylureas. Possible signs include shakiness, sweating, fast heartbeat, confusion, or feeling weak [1].
When do blood sugar changes usually start?
Blood sugar improvements can begin soon after starting treatment as it affects how food is digested and how the body regulates insulin and glucagon. Dose increases are typically gradual, and blood sugar effects often track with reaching higher doses over time [1].
What should people monitor while using semaglutide?
Patients commonly monitor blood glucose at home (if advised) and track symptoms that could suggest hypoglycemia or other side effects. Clinicians also monitor A1C and may adjust other diabetes medications to reduce hypoglycemia risk when starting or increasing semaglutide [1].
Sources
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637